ARC
SUPN icon

Advisor Resource Council’s Supernus Pharmaceuticals SUPN Stock Holding History

Advisor Resource Council’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-78,245
Closed -$2.28M – 503
2021
Q4 		$2.28M Buy
78,245
+27,037
+53% +$820K 0.18% 118
2021
Q3 		$1.37M Buy
+51,208
New +$1.37M 0.41% 66

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advisor Resource Council's SUPN Position: Q1 2022 in Review

Advisor Resource Council sold out of Supernus Pharmaceuticals (SUPN) in Q1 2022, closing a stake of 78,245 shares — an estimated $2.28M sold.

Advisor Resource Council first reported a position in SUPN in Q3 2021 and held it in 2 quarters. The position peaked at $2.28M in Q4 2021. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

  • Advisor Resource Council reported no remaining Supernus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Advisor Resource Council sold 78,245 Supernus Pharmaceuticals shares in Q1 2022, an estimated $2.28M.
  • Advisor Resource Council first reported a position in Supernus Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Advisor Resource Council's Supernus Pharmaceuticals position peaked at $2.28M in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Advisor Resource Council's 13F filing for Q1 2022, filed 20 Apr 2022.